TTPH Tetraphase Pharmaceuticals Inc.

1.51
-0.07  -4%
Previous Close 1.58
Open 1.58
Price To Book 0.83
Market Cap 80974833
Shares 53,625,717
Volume 541,071
Short Ratio
Av. Daily Volume 614,488

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 181171880
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171028
  3. 8-K - Current report 181169783
  4. 8-K - Current report 181160010
  5. 8-K - Current report 181079228

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial also did not meet primary endpoints - noted February 13, 2018.
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
FDA approval announced August 27, 2018.
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)
Phase 1 trial to be completed 2Q 2019.
TP-271
Community-acquired bacterial pneumonia (CABP)

Latest News

  1. Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference
  2. Report: Exploring Fundamental Drivers Behind Resonant, Constellation Brands, Masimo, Tetraphase Pharmaceuticals, LivaNova, and Penumbra — New Horizons, Emerging Trends, and Upcoming Developments
  3. Edited Transcript of TTPH earnings conference call or presentation 8-Nov-18 9:30pm GMT
  4. Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Lags Revenue Estimates
  5. Tetraphase: 3Q Earnings Snapshot
  6. Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  7. Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
  8. Tetraphase Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call
  9. War against the superbugs: Mass. biotechs step up to fight antibiotic resistance
  10. Is Tetraphase Pharmaceuticals Inc’s (NASDAQ:TTPH) Balance Sheet Strong Enough To Weather A Storm?
  11. Tetraphase Pharmaceuticals Announces Positive Data from Post-Hoc Analysis of Phase 3 Trials Demonstrating Efficacy of XERAVA™ (eravacycline) in Obese and Renally Impaired Patients with Complicated Intra-Abdominal Infections
  12. Consolidated Research: 2018 Summary Expectations for Vuzix, BCE, Tetraphase Pharmaceuticals, T2 Biosystems, TPG Specialty Lending, and Jianpu Technology — Fundamental Analysis, Key Performance Indications
  13. Tetraphase Pharmaceuticals Announces Presentation of Positive Data from Phase 3 Trials of XERAVA™ (eravacycline) and Multiple-Ascending Dose Trial of TP-6076 at IDWeek 2018
  14. Options Traders Expect Huge Moves in Tetraphase (TTPH) Stock
  15. DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  16. Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. (TTPH)
  17. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tetraphase Pharmaceuticals, Inc. - TTPH
  18. Tetraphase Pharmaceuticals to Present at the Cantor Global Healthcare Conference

SEC Filings

  1. CT ORDER - Confidential treatment order 181171880
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171028
  3. 8-K - Current report 181169783
  4. 8-K - Current report 181160010
  5. 8-K - Current report 181079228
  6. 8-K - Current report 181040307
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988201
  8. 8-K - Current report 18875117
  9. CT ORDER - Confidential treatment order 18817600
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18803890